Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Salvianolic acid C protects against sepsis-associated acute kidney injury through promotion of PGC1α-mediated renal gluconeogenesis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Qiming, Tan Bo, Lin Pinglan, Wang Ye, Huang Di, Yang Xuejun, Lu Jianrao, Chen Dongping, Hu Jing, Li Lin, Wu Ming
Аннотация
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) remains a critical clinical challenge with no effective targeted therapies available.
PURPOSE: This study aimed to investigate the therapeutic potential of salvianolic acid C (SAC) in SA-AKI and elucidate its underlying molecular mechanisms.
METHODS: SA-AKI models were established in renal cells and mice via LPS stimulation. RNA sequencing was performed to dissect the downstream mechanisms of SAC in SA-AKI. The downstream mechanisms were validated by qPCR, Western blotting, molecular docking, immunohistochemical staining, surface plasmon resonance, and cellular thermal shift assay.
RESULTS: Administration of SAC significantly improved renal function, alleviated tubular injury, suppressed renal inflammation in septic mice. Consistent with these findings, SAC exhibited potent anti-inflammatory effects in LPS-treated renal tubular epithelial cells. RNA sequencing identified gluconeogenesis as a significantly enriched pathway modulated by SAC treatment, which was further validated at mRNA, protein and metabolic levels. The critical role of renal gluconeogenesis in SA-AKI was confirmed through genetic deletion or overexpression of the gluconeogenic enzyme PCK1 in both renal cells and mouse kidneys. Notably, PCK1 deletion abolished SAC-mediated protection in SA-AKI models. Further experiments revealed that SAC restored renal gluconeogenesis through directly binding to and upregulating PGC1α. Mechanistic studies showed that SAC treatment reduced histone H3 lysine 18 lactylation-mediated inflammatory responses in SA-AKI, an effect dependent on PCK1 activity and reversed by lactate supplementation.
CONCLUSION: Our findings uncover a novel PGC1α-gluconeogenesis-histone lactylation axis through which SAC protects against SA-AKI, thereby highlighting metabolic regulation as a promising therapeutic strategy for SA-AKI.
PURPOSE: This study aimed to investigate the therapeutic potential of salvianolic acid C (SAC) in SA-AKI and elucidate its underlying molecular mechanisms.
METHODS: SA-AKI models were established in renal cells and mice via LPS stimulation. RNA sequencing was performed to dissect the downstream mechanisms of SAC in SA-AKI. The downstream mechanisms were validated by qPCR, Western blotting, molecular docking, immunohistochemical staining, surface plasmon resonance, and cellular thermal shift assay.
RESULTS: Administration of SAC significantly improved renal function, alleviated tubular injury, suppressed renal inflammation in septic mice. Consistent with these findings, SAC exhibited potent anti-inflammatory effects in LPS-treated renal tubular epithelial cells. RNA sequencing identified gluconeogenesis as a significantly enriched pathway modulated by SAC treatment, which was further validated at mRNA, protein and metabolic levels. The critical role of renal gluconeogenesis in SA-AKI was confirmed through genetic deletion or overexpression of the gluconeogenic enzyme PCK1 in both renal cells and mouse kidneys. Notably, PCK1 deletion abolished SAC-mediated protection in SA-AKI models. Further experiments revealed that SAC restored renal gluconeogenesis through directly binding to and upregulating PGC1α. Mechanistic studies showed that SAC treatment reduced histone H3 lysine 18 lactylation-mediated inflammatory responses in SA-AKI, an effect dependent on PCK1 activity and reversed by lactate supplementation.
CONCLUSION: Our findings uncover a novel PGC1α-gluconeogenesis-histone lactylation axis through which SAC protects against SA-AKI, thereby highlighting metabolic regulation as a promising therapeutic strategy for SA-AKI.